Description
Release form
Cardiask tablets, enteric coated with a white color, round, biconvex, with a smooth shiny surface, light roughness is allowed.
Pharmacological action
Pharmaceutical group: NSAIDs.
Pharmaceutical action: The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase (COX-1), as a result of which thromboxane A2 synthesis is blocked and platelet aggregation is suppressed.
It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands the scope of its application for various vascular diseases.
ASA also has anti-inflammatory, analgesic, antipyretic effect.
Pharmacokinetics: After taking the CardIASA drug inside, acetylsalicylic acid is absorbed in the upper small intestine. The maximum plasma concentration is observed on average 3 hours after ingestion of the drug. Acetylsalicylic acid undergoes partial metabolism in the liver with the formation of less active metabolites.
It is excreted by the kidneys, both unchanged and in the form of metabolites: the half-life for acetylsalicylic acid is about 15 minutes, for metabolites – about 3 hours.
Indications
Prevention of acute myocardial infarction in the presence of risk factors (e.g., diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, advanced age) and recurrent myocardial infarction
Unstable angina pectoris
Prevention of stroke (including in patients with transient cerebrovascular disease)
Prevention of transient cerebrovascular accident
Prevention of thromboembolism and surgery, and after surgery carotid arteries, arteriovenous shunting, carotid artery angioplasty)
Prevention of deep vein thrombosis and pulmonary embolism and e branches (e.g., prolonged immobilization resulting large surgical intervention).
Special instructions
CardiAsk should be used after prescribing a doctor.
ASA can provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors are a history of asthma, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions to other drugs (eg, skin reactions, itching, urticaria).
ASA can cause bleeding of varying severity during and after surgery.
The combination of ASA with anticoagulants, thrombolytics and antiplatelet drugs is associated with an increased risk of bleeding.
ASA in low doses can trigger the development of gout in susceptible individuals (with decreased uric acid excretion).
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the blood.
High doses of ASA have a hypoglycemic effect, which must be kept in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.
The combined use of corticosteroids and salicylates should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the cancellation of corticosteroids, an overdose of salicylates is possible.
The combination of ASA with ibuprofen is not recommended, since the latter worsens the beneficial effect of ASA on life expectancy.
An excess dose of ASA is associated with a risk of gastrointestinal bleeding.
Overdose is especially dangerous in elderly patients.
Combined with ASA and alcohol, there is an increased risk of damage to the gastrointestinal mucosa and prolonged bleeding time.
Composition
1 tablet: – acetylsalicylic acid 50 mg, 100 mg or 300 mg
Excipients: corn starch, lactose, microcrystalline cellulose, plaston K-90, t-Calcium stete, calcium stea MAE 100P, plasdon S-630, propylene glycol, talc, castor oil, titanium dioxide.
Dosage and administration of
CardiASK ® should be taken orally, before meals, with plenty of fluids.
CardiASK ® is intended for long-term use. The duration of therapy is determined by the attending physician.
– Prevention of suspected acute myocardial infarction
100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
– Prevention of first-time acute myocardial infarction in the presence of risk factors
100 mg per day or 300 mg every other day.
– Prevention of myocardial infarction. Unstable angina pectoris. Prevention of stroke and transient cerebrovascular accident. Prevention of thromboembolic complications after surgery or invasive studies
100 ² 300 mg per day
– Prevention of deep vein thrombosis and pulmonary embolism and its branches
100 ² 200 mg per day or 300 mg every other day.
Side effects
Allergic reactions: urticaria, Quincke’s edema.
From the digestive tract :: nausea, heartburn, vomiting, pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, including perforated, gastrointestinal bleeding, increased activity of liver enzymes.
From the respiratory system: bronchospasm.
On the part of the immune system: anaphylactic reactions.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the central nervous system: dizziness, tinnitus.
Drug Interactions
With the simultaneous use of ASA enhances the action of the following drugs: – methotrescata due to a decrease in renal clearance and its displacement from association with
proteins – heparin and indirect anticoagulants due to impaired platelet function and displacement of indirect anticoagulants from association with
proteins – thrombotic and antiplatelet drugs due to its decrease in ticlopidine excretion)
– antidiabetic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from communication with
proteins – valproic acid due to displacement from its association with proteins.
An additive effect is observed while taking ASA with alcohol.
ASA weakens the action of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
Strengthening the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effect.
Overdose
Overdose Symptoms CardiASK moderate: Nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment:
Dose reduction.
Symptoms of an overdose of severe CardiASK:
Fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.
Treatment: immediate hospitalization in specialized departments for emergency therapy – gastric lavage, determination of acid-base condition, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated charcoal, symptomatic therapy. When carrying out alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when the concentration of salicylates in the blood plasma is more than 500 mg / l (3.6 mmol / l) in adults and 300 mg / l (2 , 2 mmol / l) in children.
Pharmacy terms
No prescription
lekarstvennaja form
tablets
Indications
Prevention trombozov, Prevention Ostrog myocardial infarction, angina, prevention infarktov and insulytov, Prevention tromboÑmboliy, breach mozgovogo krovoobrashteniya
Kanonfarma, Russia
